Download this press release (296 KB).
ROSEVILLE, MN (November 02, 2017) — Rebiotix Inc., a clinical-stage microbiome company focused on harnessing the power of the human microbiome to treat challenging diseases, and the C. diff. Foundation have joined today to voice support for the State of Minnesota in declaring November “C. Difficile Infection Awareness Month.” Rebiotix and the C. diff. Foundation believe this important action by Governor Mark Dayton and his administration adds significant weight to the ongoing effort to prevent and treat Clostridium difficile infection (C. diff.), which is a national health concern resulting in more than 500,000 infections and 29,000 deaths annually.
“C. diff. infection is a debilitating and potentially life-threatening condition that is now recognized as the number one healthcare associated infection in the U.S.,” said Lee Jones, president and CEO of Rebiotix. “Increasing the awareness of this disease is important. We applaud both the C. diff. Foundation and the State of Minnesota in its effort to build awareness of this significant health concern and welcome the opportunity to be at the forefront of developing a potentially new treatment for patients to address the most challenging of C. diff. infections.”
Rebiotix’s first product, RBX2660, is intended to prevent recurrent C. diff. infections. RBX2660 is currently the subject of a randomized, double-blind, placebo-controlled Phase 3 clinical trial to evaluate its efficacy and safety for the prevention of recurrent C. diff. infection and is Rebiotix’s most clinically advanced drug product developed from the company’s Microbiota Restoration Therapy™ (MRT) platform. Rebiotix is also advancing RBX7455, a lyophilized, non-frozen, oral capsule formulation of its MRT technology in an investigator sponsored Phase 1 study for the prevention of recurrent C. diff. infection.
“The ability to prevent and potentially eradicate recurrent C. diff. infection requires leadership from across the landscape of healthcare, from government institutions to advocacy to academia to emerging biotechnology companies,” said Nancy Caralla, founder of the C. diff. Foundation. “We commend the State of Minnesota and Rebiotix as each seeks to play an important role in reducing the rate and impact of C. diff. infection.”
About Clostridium difficile Infection
Clostridium difficile (C. diff.) infection is a serious and potentially fatal gastrointestinal disease, characterized by severe diarrhea, fever, and loss of appetite. It is a leading healthcare-associated infection (HAI), and in the U.S. alone, there are about 500,000 people infected and over 29,000 deaths annually from the disease. Currently, 20-30% of patients with C. diff. go on to experience more than one episode of the disease, which is known as recurrent C. diff. infection. Recurrent C. diff. infection is especially challenging to treat as, to date, there are no approved microbial-based drugs to treat patients with two or more recurrences.
About the C. diff. Foundation
The C. diff. Foundation, a 501(c) (3) non-profit organization, established in 2012, and comprised of 100% volunteering professionals dedicated at supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety, and support worldwide. The Foundation’s founder is a Nurse and after suffering through C. difficile infections herself and witnessing the loss of her Father, whose life was claimed by C. difficile involvement, the C. diff. Foundation came to fruition. The C. diff. Foundation Members, with their Volunteer Patient Advocates, successfully “Raise C. diff. Awareness” nationwide and in fifty-six (56) countries and host a U.S. Nationwide information Hot-Line (1-844-FOR-CDIF) to support health care providers, patients, and families manage through the difficulties of a C. diff. infection among many other programs.
About Rebiotix Inc.
Rebiotix Inc. is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of challenging diseases. Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff) infection. RBX2660 has been granted Fast Track status and Breakthrough Therapy designation from the FDA for its potential to prevent recurrent C. diff. infection. Rebiotix’s clinical pipeline also features RBX7455, a lyophilized non-frozen, oral capsule formulation, which is currently the subject of an investigator-sponsored Phase 1 trial for the prevention of recurrent C. diff. infection. In addition, Rebiotix is targeting several other disease states with drug products built on its pioneering Microbiota Restoration TherapyTM (MRT) platform. MRT is a standardized, stabilized drug technology that is designed to rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient’s intestinal tract via a ready-to-use and easy-to-administer format. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit www.rebiotix.com.
Rebiotix Media Contact:
Tiberend Strategic Advisors